TOI Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

2.765

Open

2.655

VWAP

2.71

Vol

514.72K

Mkt Cap

256.78M

Low

2.650

Amount

1.40M

EV/EBITDA(TTM)

--

Total Shares

98.38M

EV

305.38M

EV/OCF(TTM)

--

P/S(TTM)

0.49

The Oncology Institute, Inc. is a value-based oncology company. The Company manages community-based oncology practices which serve patients at approximately 86 clinic locations across 16 markets and five states throughout the United States. The Company's segment includes patient services, dispensary, and clinical trials & other. Its managed clinics provide a range of medical oncology services, including physician services, in-house infusion, radiation, and programs like outpatient blood product transfusions, along with 24/7 patient support. The Company, through TOI Clinical Research, LLC (TCR), provides and manages clinical trial services and research for the benefit of cancer patients. The Company also provides management services to over 14 clinic locations owned by independent oncology practices. The Company and its affiliated providers have contractual relationships with payors serving a variety of patients, including Medicare Advantage (MA), Medicaid, and commercial patients.

Show More

Events Timeline

(ET)

2026-02-23

08:10:00

Oncology Institute Appoints Kim Tzoumakas to Board of Directors

2026-01-12 (ET)

2026-01-12

08:10:00

TOI Projects Total Revenue of $650 Million for 2026

2026-01-12

08:10:00

Company Projects 20% Annual Revenue Growth by 2028

2026-01-09 (ET)

2026-01-09

08:10:00

Oncology Institute Appoints New CIO and CPO

2026-01-05 (ET)

2026-01-05

08:50:00

The Oncology Institute Appoints Mark Stolper to Board of Directors

2025-12-01 (ET)

2025-12-01

08:40:00

Oncology Institute Board Member Resigns, Search for New Independent Directors Initiated

News

Newsfilter

02-26Newsfilter

The Oncology Institute to Release 2025 Financial Results

Globenewswire

01-09Globenewswire

M33 Growth Partners with US Neurology Associates to Transform Neurology Care

Newsfilter

01-09Newsfilter

The Oncology Institute Appoints New CIO and CPO to Enhance Leadership in Value-Based Cancer Care

NASDAQ.COM

2025-12-18NASDAQ.COM

Biotech Sector Sustains After-Hours Trading Gains

Benzinga

2025-11-25Benzinga

Needham Begins Coverage of Oncology Institute with Buy Rating and Sets Price Target at $5

Benzinga

2025-11-21Benzinga

Major Stocks Including Elastic, Veeva Systems, and HIVE Digital Decline in Friday's Pre-Market Trading

3 Analyst Rating

Wall Street analysts forecast TOI stock price to rise

3 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

5.00

Averages

6.67

High

8.00

Current: 0.000

Low

5.00

Averages

6.67

High

8.00

Needham

Buy

initiated

$5

AI Analysis

2025-11-25

Reason

Needham

Price Target

$5

AI Analysis

2025-11-25

initiated

Buy

Reason

Needham initiated coverage of Oncology Institute with a Buy rating and $5 price target. As value-based care adoption accelerates, Oncology Institute appears well positioned to help curb rising oncology costs, with early relationships typically starting in fee-for-service and expanding into downside risk, the analyst tells investors in a research note. Demand supports a durable 20%+ growth outlook, a shift toward VBC could lift EBITDA margins into the mid-single digits, and shares look undervalued ahead of expected positive EBITDA in Q4 and FY26, the firm says.

Needham

Matthew Shea

initiated

$5

2025-11-25

Reason

Needham

Matthew Shea

Price Target

$5

2025-11-25

initiated

Reason

Needham analyst Matthew Shea initiated coverage of Oncology Institute with a Buy rating and $5 price target. The need for solutions that can mitigate oncology cost trends "could not be more apparent," says the analyst, who views Oncology Institute as "a critical player in addressing this gap." The firm sees demand seeding durable 20%-plus topline growth and sees an opportunity for EBITDA margins to scale towards mid-single digits over the medium term as mix shifts towards value-based care, the analyst tells investors.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for TOI

Unlock Now

Valuation Metrics

The current forward P/E ratio for Oncology Institute Inc (TOI.O) is -10.49, compared to its 5-year average forward P/E of -6.57. For a more detailed relative valuation and DCF analysis to assess Oncology Institute Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

-6.57

Current PE

-10.49

Overvalued PE

1.36

Undervalued PE

-14.51

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

355.35

Current EV/EBITDA

8828.80

Overvalued EV/EBITDA

2153.22

Undervalued EV/EBITDA

-1442.52

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

N/A

5Y Average PS

0.52

Current PS

0.61

Overvalued PS

1.20

Undervalued PS

-0.15

Financials

AI Analysis

Annual

Quarterly

Whales Holding TOI

EdgePoint Investment Group Inc.

Centerbook Partners LP

Grandeur Peak Global Advisors, LLC

Akre Capital Management, LLC

Constellation Software Inc.

Trading Trends

People Also Watch

Frequently Asked Questions

What is Oncology Institute Inc (TOI) stock price today?

The current price of TOI is 2.715 USD — it has increased 4.02

What is Oncology Institute Inc (TOI)'s business?

The Oncology Institute, Inc. is a value-based oncology company. The Company manages community-based oncology practices which serve patients at approximately 86 clinic locations across 16 markets and five states throughout the United States. The Company's segment includes patient services, dispensary, and clinical trials & other. Its managed clinics provide a range of medical oncology services, including physician services, in-house infusion, radiation, and programs like outpatient blood product transfusions, along with 24/7 patient support. The Company, through TOI Clinical Research, LLC (TCR), provides and manages clinical trial services and research for the benefit of cancer patients. The Company also provides management services to over 14 clinic locations owned by independent oncology practices. The Company and its affiliated providers have contractual relationships with payors serving a variety of patients, including Medicare Advantage (MA), Medicaid, and commercial patients.

What is the price predicton of TOI Stock?

Wall Street analysts forecast TOI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TOI is6.67 USD with a low forecast of 5.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Oncology Institute Inc (TOI)'s revenue for the last quarter?

Oncology Institute Inc revenue for the last quarter amounts to 136.56M USD, increased 36.70

What is Oncology Institute Inc (TOI)'s earnings per share (EPS) for the last quarter?

Oncology Institute Inc. EPS for the last quarter amounts to -0.14 USD, decreased -22.22

How many employees does Oncology Institute Inc (TOI). have?

Oncology Institute Inc (TOI) has 825 emplpoyees as of March 11 2026.

What is Oncology Institute Inc (TOI) market cap?

Today TOI has the market capitalization of 256.78M USD.